KNSA (Kiniksa Pharmaceuticals International) 3-Year Revenue Growth Rate : 119.30% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Kiniksa Pharmaceuticals International 3-Year Revenue Growth Rate?

Kiniksa Pharmaceuticals International's Revenue per Share for the three months ended in Dec. 2024 was $1.69.

During the past 12 months, Kiniksa Pharmaceuticals International's average Revenue per Share Growth Rate was 57.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 119.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 9 years, the highest 3-Year average Revenue per Share Growth Rate of Kiniksa Pharmaceuticals International was 119.30% per year. The lowest was 119.30% per year. And the median was 119.30% per year.

Competitive Comparison of Kiniksa Pharmaceuticals International's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiniksa Pharmaceuticals International's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals International's 3-Year Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

Kiniksa Pharmaceuticals International 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Kiniksa Pharmaceuticals International (NAS:KNSA) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Kiniksa Pharmaceuticals International 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals International's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiniksa Pharmaceuticals International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kiniksa Pharmaceuticals International PLC (NAS:KNSA) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

23 Old Bond Street, Floor 3, London, GBR, W1S 4PZ

Website

https://www.kiniksa.com

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Executives

Eben Tessari	officer: Chief Business Officer	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Mark Ragosa	officer: Interim CFO	C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421
Michael R Megna	officer: Chief Accounting Officer	1050 HINGHAM STREET, ROCKLAND MA 02370
Sanj K Patel	director, 10 percent owner, officer: Chairman & CEO	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Ross Moat	officer: Group VP & Rilonacept GM	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
John Paolini	officer: Chief Medical Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Barry D Quart	director	C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549
Felix Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Arian Pano	officer: Chief Clinical Dev. Officer	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham	10 percent owner, officer: Chief Legal Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
G Bradley Cole	director	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063